Clinical trials: Lung Fibrosis
Cystic Fibrosis
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).
- Trial name
- KONTINUE (NCT01707290)
- Testing
- Ivacaftor
- Where
- 38 sites in United States, Belgium and 2 more
- Volunteers
- 125 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Fibrosis
The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib
The aim of this study is to describe patients' satisfaction with Patient Support Program (Balance Program), Quality of Life and depression symptoms, dosing pattern, disease symptoms, adverse events and nintedanib discontinuation…
- Trial name
- NCT06912659
- Where
- Spain
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis
Illness Expectations in Pulmonary Fibrosis
This study aims to delve into the constructs of illness beliefs and expectations among patients with Pulmonary Fibrosis, exploring how these beliefs and expectations may influence the treatment journey, including oxygen therapy…
- Trial name
- CAMFP (NCT06327360)
- Testing
- Psychological questionnaires
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Cystic Fibrosis
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy
The trial will consist of a single treatment group enrolling adult subjects with CF on background therapy with KALYDECO®. Approximately 16 subjects will be enrolled.
- Trial name
- NCT03258424
- Testing
- PTI-428
- Where
- 2 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Proteostasis Therapeutics, Inc.
COVID-19, Pulmonary Fibrosis
Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands
To date, little is known about the short and long-term complications of COVID-19. In order to obtain more insights in disease course and recovery of COVID-19 and to improve care after hospital admission, patients with COVID-19…
- Trial name
- HOMECOMIN' (NCT04488562)
- Where
- 3 sites in Netherlands
- Volunteers
- 133 people
- Sponsor
- Erasmus Medical Center
Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis)
Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)
EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven.
- Conditions
- Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis), Persistent Bacteremia, Pulmonary Infection
- Trial name
- EPHICACI (NCT06368388)
- Testing
- Prospective data collection phage therapy, Prospective data collection standard-of-care
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
IPF
Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
This is an open-label Phase I/II trial to assess the feasibility and safety of combined plasma exchange (PEX), rituximab, and conventional corticosteroid administration on the outcome of hospitalized patients with acute IPF…
- Trial name
- NCT01266317
- Testing
- Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Michael Donahoe
Cystic Fibrosis
The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis
This study will assess whether rhDNase treatment improves ventilation inhomogeneity as assessed by lung clearance index (LCI) in patients with cystic fibrosis (CF).
- Trial name
- NCT00557089
- Testing
- rhDNAse
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- The Hospital for Sick Children
Cystic Fibrosis
Clinical Impact of MI on Inhaled Antibiotic Adherence in Cystic Fibrosis
Adherence to treatment is a major challenge in cystic fibrosis (CF). Motivational Interviewing (MI) is increasingly used to address this, but its effectiveness is unknown.
- Trial name
- NCT04017559
- Testing
- Motivational Interviewing
- Volunteers
- 22 people
- Sponsor
- Belfast Health and Social Care Trust
Cystic Fibrosis
Study for Evaluating the Real Use of Inhaled Aztreonam Lysine in Patients With Cystic Fibrosis
The aim of this observational trial is to evaluate the pulmonary function in cystic fibrosis patients that have been treated with inhaled aztreonam lysine comparing the previous 12 months before the treatment and the forward 12…
- Trial name
- REALIZA-FQ (NCT03607396)
- Where
- 3 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Cystic Fibrosis
Tissue Bank for Pulmonary Diseases
The aim of this research study is to collect and store the specimens that are left over after patients undergo tests ordered by their physicians.
- Trial name
- NCT00546962
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Boston Children's Hospital
Non-cystic Fibrosis Bronchiectasis
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
- Trial name
- iBEST-1 (NCT02712983)
- Testing
- TIP
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis in Children
Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis
This study aims to assess the effects of programmed exercise combined with CFTR protein modulator drugs in the cardiorespiratory fitness, strength, functional capacity and agility in a group of young patients with Cystic Fibrosis.
- Trial name
- NCT04415268
- Testing
- Exercise, Unsupervised exercise, CFTR Modulators
- Where
- Spain
- Sponsor
- Universidad Europea de Madrid
Cystic Fibrosis
Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis
The purpose of this research study is to determine whether the combination of inhaled amiloride and a concentrated salt solution is better than the salt solution itself for cystic fibrosis (CF) patients.
- Trial name
- NCT00274391
- Testing
- 7% NaCl, Amiloride HCl
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina
Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05671835
- Testing
- TTI-101
- Where
- 28 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tvardi Therapeutics, Incorporated
SARS-CoV-2 Infection, Lung Fibrosis
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
The innovative drug Treamid is planned for use in the treatment of patients with persistent lung damage and reduced exercise tolerance exertion after COVID-19 pneumonia in a multicenter, randomized, double-blind…
- Trial name
- NCT05516550
- Testing
- Treamid, Treamid twice a day, Treamid once a day
- Volunteers
- 412 people
- Sponsor
- PHARMENTERPRISES LLC
Fibrosis, Pulmonary
Inspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a fibrosing progressive interstitial lung disease with unknown etiology, with a median survival of 3 years since first diagnosis.
- Trial name
- NASA (NCT05310669)
- Testing
- Nasal pressure assessment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Modena and Reggio Emilia
Cystic Fibrosis
Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients
The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients. The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the…
- Trial name
- SPutOM-CF (NCT04735679)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Montpellier
Pulmonary Fibrosis, Lung Diseases
Linkage Study in Familial Pulmonary Fibrosis
To map the gene (or genes) for familial pulmonary fibrosis.
- Conditions
- Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial
- Trial name
- NCT00016627
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)